Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (Q46505738)

22 December 2017

title

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma (English)

1 reference

22 December 2017

author name string

I Breitkreutz

1

1 reference

22 December 2017

M S Raab

2

1 reference

22 December 2017

S Vallet

3

1 reference

22 December 2017

T Hideshima

4

1 reference

22 December 2017

N Raje

5

1 reference

22 December 2017

C Mitsiades

6

1 reference

22 December 2017

D Chauhan

7

1 reference

22 December 2017

Y Okawa

8

1 reference

22 December 2017

N C Munshi

9

1 reference

22 December 2017

P G Richardson

10

1 reference

22 December 2017

K C Anderson

11

1 reference

22 December 2017

publication date

3 July 2008

1 reference

22 December 2017

published in

Leukemia

1 reference

22 December 2017

volume

22

1 reference

22 December 2017

issue

10

1 reference

22 December 2017

page(s)

1925-1932

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1038/leu.2008.174

exact match

0 references

cites work

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Bortezomib inhibits human osteoclastogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Biosynthesis and processing of cathepsin K in cultured human osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Osteopetrosis in mice lacking haematopoietic transcription factor PU.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

RANK ligand and osteoprotegerin in myeloma bone disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

Bone and haematopoietic defects in mice lacking c-fos

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

7 January 2021

Novel therapies targeting the myeloma cell and its bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

7 January 2021

BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

7 January 2021

Immunocytochemistry reveals RANKL expression of myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.174

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.174

1 reference

22 December 2017

Dimensions Publication ID

0 references

1 reference

22 December 2017